ArticleBMJ public health2025
Clinical characteristics of COVID-19 in children and adolescents: insights from an Italian paediatric cohort using a machine-learning approach.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SARS-CoV-2 Infection in Children: Revisiting Host-Virus Interactions Through Post-Infection Immune Profiling.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The epidemiology and clinical characteristics of COVID-19 evolved due to new SARS-CoV-2 variants of concern (VOCs). The Omicron VOC's higher transmissibility increased paediatric COVID-19 cases and hospital admissions. Most research during the Omicron period has focused on hospitalised cases, leaving a gap in understanding the disease's evolution in community settings. This study targets children with mild to moderate COVID-19 during pre-Omicron and Omicron periods. It aims to identify patterns in COVID-19 morbidity by clustering individuals based on symptom similarities and duration of symptoms and develop a machine-learning tool to classify new cases into risk groups. Methods: We propose a data-driven approach to explore changes in COVID-19 characteristics by analysing data from 581 children and adolescents collected within a paediatric cohort at the University Hospital of Padua. First, we apply an unsupervised machine-learning algorithm to cluster individuals into groups. Second, we classify new patient risk groups using a random forest classifier model based on sociodemographic information, pre-existing medical conditions, vaccination status and the VOC as predictive variables. Third, we explore the key features influencing the classification through the SHapley Additive exPlanations. Results: The unsupervised clustering identified three severity risk profile groups. Cluster 0 (mildest) had an average of 1.2 symptoms (95% CI 0.0 to 5.0) and mean symptom duration of 1.26 days (95%CI 0.0 to 9.0), cluster 1 had 2.27 symptoms (95% CI 1.0 to 6.0) lasting 3.47 days (95% CI 1.0 to 12.0), while cluster 2 (strongest symptom expression) exhibited 3.41 symptoms (95% CI 2.0 to 7.0) over 5.52 days (95% CI 0.0 to 16.0). Feature importance analysis showed that age was the most important predictor, followed by the variant of infection, influenza vaccination and the presence of comorbidities. The analysis revealed that younger children, unvaccinated individuals, those infected with Omicron and those with comorbidities were at higher risk of experiencing a greater number and longer duration of symptoms. Conclusions: Our classification model has the potential to provide clinicians with insights into the children's risk profile of COVID-19 using readily available data. This approach can support public health by clarifying disease burden and improving patient care strategies. Furthermore, it underscores the importance of integrating risk classification models to monitor and manage infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.